Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 489-493 , July 2009

Positron emission tomography imaging of (2R,3R)-5-[18F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter

Received 23 January 2009 ,Revised 12 February 2009 ,Accepted 17 February 2009.

References 

  1. Parsons SM, Prior C, Marshall IG. Acetylcholine transport, storage and release. Int Rev Neurobiol. 1993;35:279–390
  2. Frey KA, Wieland DM, Kilbourn MR. Imaging of monoaminergic and cholinergic vesicular transporters in the brain. In:  Goldstein D,  Eisenhofer G,  McCarty R editor. Catecholamines: Bridging Basic Science with Clinical Medicine. San Diego: Academic Press; 1997;p. 269–272
  3. Efange SM. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J. 2000;14:2401–2413
  4. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol. 1996;40:399–410
  5. Albin RL, Cross D, Cornblath WT, Wald JA, Wernette K, Frey KA, et al. Diminished striatal [123I]iodobenzovesamicol binding in idiopathic cervical dystonia. Ann Neurol. 2003;53:528–532
  6. Gilman S, Chervin RD, Koeppe RA, Consens FB, Little R, An H, et al. Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA. Neurology. 2003;61:35–39
  7. Mazere J, Prunier C, Barret O, Guyot M, Hommet C, Guilloteau D, et al. In vivo SPECT imaging of vesicular acetylcholine transporter using [(123I)]-IBVM in early Alzheimer's disease. NeuroImage. 2008;40:280–288
  8. Kilbourn MR, Jung YW, Haka MS, Gildersleeve DL, Kuhl DE, Wieland DM. Mouse brain distribution of a carbon-11 labeled vesamicol derivative: presynaptic marker of cholinergic neurons. Life Sciences. 1990;47:1955–1963
  9. Widén L, Eriksson L, Ingvar M, Parsons SM, Rogers GA, Stone-Elander S. Positron emission tomographic studies of central cholinergic nerve terminals. Neurosci Lett. 1992;136:1–4
  10. Giboureau N, Emond P, Fulton RR, Henderson DJ, Chalon S, Garreau L, et al. Ex vivo and in vivo evaluation of (2R,3R)-5-[18F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse. 2007;61:962–970
  11. Shiba K, Nishiyama S, Tsukada H, Ishiwata K, Kawamura K, Ogawa K, et al. The potential of (−)-o-[11C]methylvesamicol for diagnosing cholinergic deficit dementia. Synapse. 2009;63:167–171
  12. Mulholland GK, Jung YW, Wieland DM, Kilbourn MR, Kuhl DE. Synthesis of [18F]fluoroethoxy-benzovesamicol, a radiotracer for cholinergic neurons. J Labelled Compds Radiopharm. 1993;33:583–591
  13. Mulholland GK, Wieland DM, Kilbourn MR, Frey KA, Sherman PS, Carey JE, et al. [18F]Fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse. 1998;30:263–274
  14. Rosa-Neto P, Alliaga A, Mxengeza S, Massarweh G, Landry E, Bedard MA, et al. Imaging vesicular acetylcholine transporter in rodents using [18F]fluoroethoxy-benzovesamical and microPET. J Cer Blood Flow Metab. 2007;27(Suppl 1):PP03--07M

☆ This work was supported by grants from the National Institutes of Health (MH66506) and the Office of Science, US Department of Energy (DE-FG02-87ER60561).

PII: S0969-8051(09)00052-3

doi: 10.1016/j.nucmedbio.2009.02.007

Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 489-493 , July 2009

Article Tools

* Image Usage & Resolution